Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933056 · ClinicalTrials.gov registry record · Early Phase 1
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
A Early Phase 1 study of Platelet Function and Reactivity Tests, sponsored by University of Michigan.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06933056: Recruiting Early Phase 1 study of Platelet Function and Reactivity Tests, sponsored by University of Michigan.
NCT06933056 is a Early Phase 1 study of Platelet Function and Reactivity Tests that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06933056, a Early Phase 1 study of Platelet Function and Reactivity Tests, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Primary Outcome
Measured from blood samples
Conditions Studied
Interventions
- DRUG Sotagliflozin (SOTA) followed by 3 drugs in a random order
- DRUG Aspirin followed by 3 drugs in a random order
- DRUG Clopidogrel followed by 3 drugs in a random order
- DRUG Eliquis followed by 3 drugs in a random order
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
What NCT06933056 shows while recruiting
NCT06933056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Platelet Function and Reactivity Tests appearing as the primary indexed condition, and to 4 interventions - of which Sotagliflozin (SOTA) followed by 3 drugs in a random order is the first listed.
NCT06933056 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06933056 about?
NCT06933056 is a clinical study titled "Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs". This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
What is the current status of trial NCT06933056?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-09-02. Estimated completion is 2026-09.
What conditions does trial NCT06933056 study?
This clinical trial studies the following conditions: Platelet Function and Reactivity Tests.
What interventions are being tested in trial NCT06933056?
The interventions under investigation include: Sotagliflozin (SOTA) followed by 3 drugs in a random order (DRUG), Aspirin followed by 3 drugs in a random order (DRUG), Clopidogrel followed by 3 drugs in a random order (DRUG), Eliquis followed by 3 drugs in a random order (DRUG).
Who is sponsoring clinical trial NCT06933056?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933056 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06933056's enrollment target sits among peer trials
20 1157th of 2000 higher than 710 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI